Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2025 | $5.00 | Neutral → Buy | H.C. Wainwright |
| 4/14/2025 | $3.25 → $2.50 | Overweight | Piper Sandler |
| 5/28/2024 | $2.25 → $3.50 | Neutral → Overweight | Piper Sandler |
| 5/9/2024 | $8.00 | Neutral → Outperform | Wedbush |
| 5/6/2024 | $2.50 → $8.00 | Hold → Buy | Jefferies |
| 4/22/2024 | Underweight → Neutral | JP Morgan | |
| 11/14/2022 | $3.00 → $2.60 | Outperform → Market Perform | BMO Capital Markets |
| 7/7/2022 | $16.00 → $4.00 | Buy → Neutral | Mizuho |
4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
8-K - CytomX Therapeutics, Inc. (0001501989) (Filer)
SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
8-K - CytomX Therapeutics, Inc. (0001501989) (Filer)
SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company's board of directors. "We are excited to welcome Zhen to our board," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. "With his extensive experience and accomplishments in oncology, Zhen brings expertise that will help shape strategy across our multi-modality PROBODY® therapeutic pipeline as well as CytomX's continued growth an
SOUTH SAN FRANCISCO, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer (CMO). In this role, Dr. Chu will oversee clinical development of the Company's diversified portfolio of Probody® therapeutic candidates. "Wayne brings to CytomX substantial experience in clinical development strategy in the oncology space," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics. "His drug development experiences have contributed to multiple approvals and span therapeutic modalitie
SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that John A. Scarlett, M.D. is retiring from its board of directors, effective when his current term expires at the company's next annual meeting of stockholders, which is currently scheduled to be held on June 15, 2022. Dr. Scarlett has served as a member of the CytomX Therapeutics board since June 2016, and is currently chair of the Compensation Committee and a member of the Audit Committee. He also serves as chairman and chief executive officer of Geron Corporation. "I would like to express my s
- Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) in Patients with Advanced Colorectal Cancer (CRC) - - Initiated CX-2051 Phase 1 dose expansions at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg doses. Additional CX-2051 Phase 1 data update expected by Q1 2026 - - Planning CX-2051 Phase 2 study initiation in 1H 2026 - - CX-801 (PROBODY® Interferon alpha-2b) Phase 1a translational data in advanced melanoma expected in 2H 2025 - - Company to host conference call today at 8 a.m. EST / 5 a.m. PST - SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics,
- 28% confirmed response rate (5/18) per RECIST v1.1 in unselected patients across doses prioritized for expansion (7.2, 8.6 and 10 mg/kg Q3W) - - 3 of 7 evaluable patients (43%) with confirmed responses at upper expansion dose (10 mg/kg Q3W) - - Median progression free survival of 5.8 months as of April 7th 2025 data cutoff - - Encouraging initial safety profile with no dose limiting toxicities at data cutoff - - Planning Phase 2 study initiation in 1H 2026 - - Conference call on Monday, May 12 at 8:00 a.m. ET - SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, to
SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first quarter financial results on Monday, May 12, 2025, before the open of the U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to j
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 2:35 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations page of CytomX's website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference. About CytomX Therapeutics, Inc.CytomX is a clinical-stage, on
SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the first patient has been dosed with CX-801 in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in the ongoing Phase 1 dose escalation study (NCT06462794) evaluating safety and initial clinical activity in patients with metastatic melanoma. CX-801 is a dually masked interferon (IFN) alpha-2b PROBODY® cytokine. CX-801 has been intentionally designed by CytomX to harness the power of Interferon alpha-2b's immune stimulating properties in combination with checkpoint inhibition. In
SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced the pricing of an underwritten offering of 76,923,076 shares of its common stock at an offering price of $1.30 per share, before underwriting discounts and commissions. All of the shares are being offered by the Company. The gross proceeds from the offering are expected to be approximately $100 million before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on May 13, 2025, subject to customary closing conditions. The Company int
H.C. Wainwright upgraded CytomX Therapeutics from Neutral to Buy and set a new price target of $5.00
Piper Sandler resumed coverage of CytomX Therapeutics with a rating of Overweight and set a new price target of $2.50 from $3.25 previously
Piper Sandler upgraded CytomX Therapeutics from Neutral to Overweight and set a new price target of $3.50 from $2.25 previously